skip to main content
Refinado por: Base de dados/Biblioteca: American Society of Hematology remover tipo de recurso: Anais de Congresso remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
CD34(+) selection of autologous transplants following myeloablative therapy in patients with newly diagnosed myeloma shows no significant clinical benefit at 4 years: An EBMT phase III randomized study
Material Type:
Ata de Congresso
Adicionar ao Meu Espaço

CD34(+) selection of autologous transplants following myeloablative therapy in patients with newly diagnosed myeloma shows no significant clinical benefit at 4 years: An EBMT phase III randomized study

Bourhis, JH ; Bouko, Y ; Koscielny, S ; Greinix, H ; Derigs, G ; Salles, G ; Feremans, W ; Bakkus, M ; Apperley, J ; Samson, D ; Gahrton, G ; Pico, JL ; Goldschmidt, H

BLOOD, 2003, Vol.102 (11), p.988A [Periódico revisado por pares]

Texto completo disponível

2
CD34+selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: A randomised study from the EBMT
Material Type:
Ata de Congresso
Adicionar ao Meu Espaço

CD34+selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: A randomised study from the EBMT

Goldschmidt, H ; Bouko, Y ; Bourhis, JH ; Greinix, H ; Salles, G ; Derigs, G ; Feremans, W ; Hegenbart, U ; Bakkus, M ; Samson, D ; Gahrton, G ; Pico, JL ; Apperley, J

BLOOD, 2000, Vol.96 (11), p.558A [Periódico revisado por pares]

Texto completo disponível

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Refinar Meus Resultados

Data de Publicação 

De até

Buscando em bases de dados remotas. Favor aguardar.